Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients

被引:9
|
作者
Sanchez-Escuredo, Ana [1 ]
Fuster, David [2 ]
Rubello, Domenico [4 ]
Muxi, Africa [2 ]
Ramos, Ana [3 ]
Campos, Francisco [2 ]
Marzola, Maria Cristina [4 ]
Cook, Gary J. [5 ]
Tapias, Andres [2 ]
Torregrosa, Jose-Vicente [1 ]
机构
[1] Hosp Clin Barcelona, Dept Nephrol & Renal Transplant, Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Nucl Med, Barcelona, Spain
[3] Fdn Jimenez Diaz, Dept Nephrol, E-28040 Madrid, Spain
[4] Santa Maria Della Misericordia Hosp, Dept Nucl Med, I-45100 Rovigo, Italy
[5] Kings Coll London, Div Imaging Sci & Biomed Engn, Dept Canc Imaging, London, England
关键词
biphosphonates; bone mineral density; ibandronate; renal transplant; risedronate; BISPHOSPHONATES; OSTEOPOROSIS;
D O I
10.1097/MNM.0000000000000316
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
IntroductionBisphosphonates may aid in treating and preventing bone loss promoted by chronic immunosuppressive treatment and secondary hyperparathyroidism in renal transplant (RT) patients. However, the effectiveness of bisphosphonates is compromised by poor patient compliance. The objective of the study was to compare the effects of once monthly ibandronate with those of weekly risedronate administration on bone mineral density (BMD) and renal function in RT patients.Patients and methodsSixty-nine patients were prospectively recruited who were at least 12 months post-RT and were treated with either oral ibandronate 150mg monthly (n=35) or oral risedronate 35mg weekly (n=34). At baseline and 1 year, creatinine, calcium, alkaline phosphatase, and i-parathyroid hormone were measured, and BMD was determined by dual-energy X-ray absorptiometry.ResultsGroup I consisted of 35 patients (28 women) treated with ibandronate who were of a mean age of 6312 years. Group II consisted of 34 patients (30 women) treated with risedronate who were of a mean age of 64 +/- 10 years. Lumbar BMD was as follows: baseline T-score (group I vs. group II) of -1.7 +/- 0.8 versus -1.9 +/- 0.8 (P=NS); and annual T-score of -1.3 +/- 0.6 versus -1.4 +/- 0.8 (P=NS). After 1 year, lumbar BMD improved to reveal a T-score of -1.3 +/- 0.6 in the ibandronate group (P<0.01) and -1.4 +/- 0.8 in the risedronate group (P<0.01). Femoral BMD was as follows: baseline T-score (group I vs. group II) of -2.1 +/- 0.7 versus -2.2 +/- 0.6 (P=NS); and annual T-score of -1.8 +/- 0.9 versus -1.8 +/- 0.8 (P=NS). Cortical bone also improved in both groups, but results were not statistically significant. No changes in renal function and no adverse effects were observed.ConclusionIn RT patients with low BMD, no difference in effects on BMD, renal function, or adverse effects were observed between monthly oral ibandronate and weekly oral risedronate administration.
引用
收藏
页码:815 / 818
页数:4
相关论文
共 50 条
  • [41] Effect of low dose weekly methotrexate on bone mineral density and bone turnover
    Patel, S
    Patel, G
    Johnson, D
    Ogunremi, L
    Barron, J
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (02) : 186 - 187
  • [42] Effect of deflazacort on bone mineral density in renal transplant recipients
    Kim, MS
    Kim, YS
    Lim, SK
    Kim, SI
    Moon, JI
    Park, K
    TRANSPLANTATION PROCEEDINGS, 1998, 30 (07) : 3041 - 3042
  • [43] Statin use and bone mineral density in renal transplant recipients
    Prasad, GVR
    Chiu, R
    Nash, MM
    Zaltzman, JS
    AMERICAN JOURNAL OF TRANSPLANTATION, 2003, 3 (10) : 1320 - 1321
  • [44] Decreased bone mineral density in the pediatric renal transplant population
    Acott, PD
    Crocker, JFS
    Wong, JA
    PEDIATRIC TRANSPLANTATION, 2003, 7 (05) : 358 - 363
  • [45] Bone mineral density (BMD) and puberty in pediatric renal transplant (Tx) patients.
    Ellis, EN
    Gimon, D
    Belsha, C
    Wells, T
    Berry, P
    Seibert, J
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1996, 7 (09): : A3419 - A3419
  • [46] Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
    Makras, Polyzois
    Petrikkos, Panagiotis
    Anastasilakis, Athanasios D.
    Kolynou, Artemis
    Katsarou, Angeliki
    Tsachouridou, Olga
    Metallidis, Symeon
    Yavropoulou, Maria P.
    BONE REPORTS, 2021, 15
  • [47] Changes in bone mineral density in patients with Paget's disease treated with risedronate
    Patel, S
    Pearson, D
    Bhallah, A
    Maslanka, W
    White, DA
    Hosking, DJ
    ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (07) : 405 - 409
  • [48] Effects of Risedronate on Bone Mineral Density and Bone Metabolic Markers in Patients with Liver Transplantation.
    Guadalix, Sonsoles
    Martinez, Guillermo
    Vargas, Carmela
    Sanchez, Raquel
    Partida, Miriam
    Moreno, Enrique
    Hawkins, Federico
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [49] Significant increases in bone mineral density observed from 1 to 2 years in women with PMO after treatment with monthly oral ibandronate.
    Miller, P. D.
    Simonelli, C.
    Leweicki, E. M.
    Barr, C. E.
    Genant, H. K.
    Zaidi, M.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S289 - S289
  • [50] Low bone mineral density in patients with mild to moderate renal failure.
    Rix, M
    Olgaard, K
    Andreassen, H
    Langdahl, B
    Eskildsen, P
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : T764 - T764